Shani Koshrovski-Michael

Shani Koshrovski-Michael

Auto-generated profile, based on publicly available information

Shani Koshrovski-Michael

Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Sabina PozziSabina Pozzi
Sabina Pozzi
ASAnna Scomparin
Anna Scomparin
SDSahar Israeli Dangoor
Sahar Israeli Dangoor
DADaniel Rodriguez Ajamil
Daniel Rodriguez Ajamil
POPaula Ofek
Paula Ofek
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro

13 December 2024 in Science Advances
Verified
Journal Article
Open access
SKShani Koshrovski-Michael
Shani Koshrovski-Michael
DADaniel Rodriguez Ajamil
Daniel Rodriguez Ajamil
PDPradip Dey
Pradip Dey
RKRon Kleiner
Ron Kleiner
STShahar Tevet
Shahar Tevet
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro
Combined therapies in cancer treatment aim to enhance antitumor activity. However, delivering multiple small molecules imposes challenges, as different drugs have distinct pharmacokinetic profiles and tumor penetration abilities, affecting their therapeutic efficacy. To circumvent this, poly(lactic-co-glycolic acid) (PLGA)–polyethylene glycol (PEG)–based nanoparticles were developed as a platform for the codelivery of synergistic drug ratios, improving therapeutic efficacy by increasing the percentage of injected dose reaching the tumor. Nonetheless, extravasation-dependent tumor accumulation is susceptible to variations in tumor vasculature; therefore, PLGA-PEG was modified with sulfates to actively target P-selectin–expressing cancers. Here, we show the potential of our platform in unique three-dimensional (3D) in vitro and in vivo models. The P-selectin–targeted nanoparticles showed enhanced accumulation in 3D spheroids and tissues of P-selectin–expressing BRAF-mutated melanomas and BRCA-mutated breast cancers, resulting in superior in vivo efficacy and safety. This nanoplatform could advance the codelivery of a plethora of anticancer drug combinations to various P-selectin–expressing tumors.